Login / Signup

A phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected non-small-cell lung cancer with EGFR mutation (West Japan Oncology Group 11719L/ADJUST study).

Ryota ShibakiHiroaki AkamatsuTerufumi KatoKazumi NishinoMorihito OkadaTetsuya MitsudomiKazushige WakudaKenichi YoshimuraNobuyuki YamamotoKazuhiko Nakagawa
Published in: Therapeutic advances in medical oncology (2021)
Ongoing phase III trials of adjuvant ICI allow the inclusion of patients with EGFR mutation, but our current trial will provide the earliest clinical data on the efficacy of platinum-doublet chemotherapy with atezolizumab.
Keyphrases